Resero Analytics is revolutionizing drug development workflows with TurboPKTK, an advanced AI platform designed to meet the needs of pharmacokineticists and toxicokineticists working in nonclinical and clinical settings. This cutting-edge technology performs essential PK analyses, including non-compartmental analysis, then automatically generates a comprehensive report, complete with figures, tables, written text and SEND files —directly from raw concentration values.

Eliminating the Reporting Bottleneck in Drug Development

One of the most time-consuming aspects of PK and TK workflows is the generation of reports. Traditional methods require extensive time and manual effort to parse data, create tables, create graphs, write text, review  and finalize the document. These cause timeline delays that can stretch into weeks or even months. TurboPKTK eliminates these inefficiencies, reducing report generation times to mere minutes. This breakthrough accelerates reporting, enables decision-making, and helps drug development programs to progress without unnecessary delays.

Enhancing Decision Support Across Drug Development Stages

TurboPKTK is not just a tool for calculations—it is a reporting system with decision-support. The platform allows users to visualize and compare PK and TK data to make informed decisions about dose vs. exposure, regimen selection, and exposure proportionality as a function of dose, sex, and repeat administration. These insights are crucial for ensuring the continued success of therapeutic assets and optimizing clinical outcomes.

The “Turbo” Advantage: Speed and Efficiency Without Compromise

As the name suggests, TurboPKTK enhances performance with speed and efficiency. Unlike conventional NCA software, this platform delivers complete reports, and it does so with both speed and efficiency. By integrating robust automation with interactive data visualizations, TurboPKTK empowers researchers to analyze PK data across studies, doses, and species with ease.

Supporting Discovery, Development, and Clinical Applications

TurboPKTK provides value across all stages of drug discovery and development:

• Discovery: Assists in lead optimization and generation by enabling rapid data analysis for numerous molecules.
• Development: Supports GLP toxicology and TK studies, ensuring regulatory compliance and accelerating progress to clinical trials. SEND file generation accelerates submission timelines. 
• Clinical: Aids clinical pharmacologists and biometrics teams in analyzing PK and safety data, ultimately informing dosage and regimen decisions. SEND file generation accelerates submission timelines. 

Seamless Reporting for Regulatory Compliance

As drug development progresses, regulatory requirements demand extensive reporting on historical data. TurboPKTK simplifies this process by enabling researchers to retrieve and compile fully traceable reports from past studies. Instead of spending valuable time reconstructing data, teams can generate regulatory-compliant reports instantly—ensuring seamless transitions from discovery to development and beyond.

Who Benefits from TurboPKTK?

TurboPKTK serves a broad spectrum of professionals, including:

• Pharmacokineticists conducting DMPK studies in pharmaceutical companies, biotech, and contract research organizations (CROs).
• Clinical Pharmacologists and Biometrics Teams involved in safety assessments and dose selection.
• Regulatory Teams requiring traceable, high-quality reports for IND and pre-IND submissions.

The Future of PK and TK Analysis

By integrating cutting-edge AI based automation with seamless reporting, interactive data visualizations, and user decision traceability, TurboPKTK redefines efficiency in PK and TK. This powerful tool enables teams to work faster, make better-informed decisions, and streamline regulatory processes—ultimately advancing drug development from discovery to commercialization with unprecedented speed and accuracy.

With TurboPKTK, Resero Analytics is setting a new standard for report generation, ensuring that researchers spend less time on analysis and reports and more time on innovation.